Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Traws Pharma's share price for the quarter that ended in Dec. 2023 was $0.7456. Traws Pharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 21.00 Mil. Therefore, Traws Pharma's market cap for the quarter that ended in Dec. 2023 was $15.66 Mil.
Traws Pharma's quarterly market cap
declined
from Jun. 2023 ($24.75 Mil) to Sep. 2023 ($14.94 Mil) but then
increased
from Sep. 2023 ($14.94 Mil) to Dec. 2023 ($15.66 Mil).
Traws Pharma's annual market cap
declined
from Dec. 2021 ($53.28 Mil) to Dec. 2022 ($13.51 Mil) but then
increased
from Dec. 2022 ($13.51 Mil) to Dec. 2023 ($15.66 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Traws Pharma's Enterprise Value for Today is $-5.12 Mil.
Traws Pharma Market Cap Historical Data
The historical data trend for Traws Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Traws Pharma's Market Cap
For the Biotechnology subindustry, Traws Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Traws Pharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Traws Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Traws Pharma's Market Cap falls into.
Traws Pharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Traws Pharma's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma (NAS:TRAW) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Traws Pharma Market Cap Related Terms
Thank you for viewing the detailed overview of Traws Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRAW has been successfully added to your 